12.53
+0.51(+4.24%)
Currency In USD
| Previous Close | 12.02 |
| Open | 12.03 |
| Day High | 12.55 |
| Day Low | 11.91 |
| 52-Week High | 12.55 |
| 52-Week Low | 5.45 |
| Volume | 1.63M |
| Average Volume | 718,098 |
| Market Cap | 685.14M |
| PE | -6.46 |
| EPS | -1.94 |
| Moving Average 50 Days | 8.97 |
| Moving Average 200 Days | 8.29 |
| Change | 0.51 |
If you invested $1000 in Zevra Therapeutics, Inc. (ZVRA) 10 years ago, it would be worth $42.17 as of July 12, 2025 at a share price of $12.53. Whereas If you bought $1000 worth of Zevra Therapeutics, Inc. (ZVRA) shares 5 years ago, it would be worth $2,827.17 as of July 12, 2025 at a share price of $12.53.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference
GlobeNewswire Inc.
Yesterday at 11:30 AM GMT
CELEBRATION, Fla., July 11, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an oral presentat
Zevra Announces Final Results of 2025 Annual Meeting of Stockholders
GlobeNewswire Inc.
May 29, 2025 8:35 PM GMT
Zevra Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the Company’s Board of Directors Board and Management Reaffirm Commitment to Driving Continued Growth and Progress Against Strategic Plan CELEBRATION, Fla., May 29, 2025 (G
All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company’s Director Nominees
GlobeNewswire Inc.
May 21, 2025 11:30 AM GMT
ISS, Glass Lewis, and Egan-Jones Unanimously Conclude Mangless Has Not Made a Compelling Case for Change Board and Management Urge Stockholders to Follow Proxy Advisors’ Recommendation and Vote “FOR” Wendy L. Dixon, Ph.D. and Tamara A. Favorito on th